Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Capital Expenditures (2016 - 2022)

Historic Capital Expenditures for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q3 2022 value amounting to $716000.0.

  • Avadel Pharmaceuticals' Capital Expenditures changed N/A to $716000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $716000.0, marking a year-over-year increase of 265384.62%. This contributed to the annual value of $716000.0 for FY2022, which is 265384.62% up from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Capital Expenditures of $716000.0 as of Q3 2022.
  • Avadel Pharmaceuticals' Capital Expenditures' 5-year high stood at $716000.0 during Q3 2022, with a 5-year trough of -$1000.0 in Q2 2019.
  • Over the past 5 years, Avadel Pharmaceuticals' median Capital Expenditures value was $37000.0 (recorded in 2018), while the average stood at $104700.0.
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Capital Expenditures skyrocketed by 54615.38% in 2018, and later plummeted by 10172.41% in 2019.
  • Quarter analysis of 5 years shows Avadel Pharmaceuticals' Capital Expenditures stood at $11000.0 in 2018, then crashed by 109.09% to -$1000.0 in 2019, then skyrocketed by 6600.0% to $65000.0 in 2020, then tumbled by 60.0% to $26000.0 in 2021, then soared by 2653.85% to $716000.0 in 2022.
  • Its Capital Expenditures stands at $716000.0 for Q3 2022, versus $26000.0 for Q1 2021 and $65000.0 for Q4 2020.